Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

Completed

Conditions: Heart Failure

Interventions: Drug: ACEI or ARB and no sacubitril/valsartan
Drug: Sacubitril/valsartan

First Posted Date: 2021-10-27

Last Posted Date: 2021-12-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1614719

Registration Number: NCT05096039

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data

Completed

Conditions: Heart Failure

Interventions: Drug: ACEi/ARB
Drug: Sacubitril/valsartan

First Posted Date: 2021-10-27

Last Posted Date: 2021-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 42269

Registration Number: NCT05096143

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Characterizing the Use of Ofatumumab in a Real World Setting

Recruiting

Conditions: Relapsing Multiple Sclerosis

Interventions: Other: ofatumumab

First Posted Date: 2021-10-22

Last Posted Date: 2023-12-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1500

Registration Number: NCT05090033

Locations: 🇦🇺
Novartis Investigative Site, Heidelberg, Australia

Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)

Phase 3

Active, not recruiting

Conditions: Type 2 Spinal Muscular Atrophy

Interventions: Genetic: OAV101
Procedure: Sham control

First Posted Date: 2021-10-22

Last Posted Date: 2024-12-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 127

Registration Number: NCT05089656

Locations: 🇮🇳
Sir Ganga Ram Hospital, New Delhi, Delhi, India
🇻🇳
National Children's Hospital, Hanoi, Vietnam
🇺🇸
Connecticut Children's Medical Center, Farmington, Connecticut, United States

and more 13 locations

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Phase 4

Recruiting

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: Disease modifying treatment (DMT)
Drug: Ofatumumab

First Posted Date: 2021-10-22

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 150

Registration Number: NCT05090371

Locations: 🇺🇸
Alabama Neurology Associates PC, Birmingham, Alabama, United States
🇺🇸
Arizona Neuroscience Research LLC, Phoenix, Arizona, United States
🇺🇸
University of California at Los Angeles, Torrance, California, United States

and more 32 locations

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

Phase 2

Terminated

Conditions: Immune Thrombocytopenia (ITP)
Cold Agglutinin Disease (CAD)

Interventions: Drug: Iptacopan

First Posted Date: 2021-10-21

Last Posted Date: 2024-06-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT05086744

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Itraconazole

Phase 1

Completed

Conditions: Malaria

Interventions: Drug: Ganaplacide
Combination Product: Lumefantrine
Drug: Itraconazole

First Posted Date: 2021-10-20

Last Posted Date: 2022-10-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT05084651

Locations: 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

Phase 4

Active, not recruiting

Conditions: Relapse Remitting Multiple Sclerosis

Interventions: Drug: Ofatumumab

First Posted Date: 2021-10-20

Last Posted Date: 2024-11-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 176

Registration Number: NCT05084638

Locations: 🇺🇸
Keck School of Medicine, Los Angeles, California, United States
🇺🇸
Neurology Associates PA, Maitland, Florida, United States
🇺🇸
Orlando Health Clinical Trials, Orlando, Florida, United States

and more 33 locations

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

Completed

Conditions: Age-related Macular Degeneration (AMD)

Interventions: Drug: Brolucizumab

First Posted Date: 2021-10-19

Last Posted Date: 2021-10-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9456

Registration Number: NCT05082415

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Iptacopan

First Posted Date: 2021-10-14

Last Posted Date: 2023-07-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 38

Registration Number: NCT05078580

Locations: 🇺🇸
Novartis Investigative Site, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy